Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

3,692JPY
11 Dec 2018
Change (% chg)

-- (--)
Prev Close
¥3,692
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,899,163
52-wk High
¥6,693
52-wk Low
¥3,678

Latest Key Developments (Source: Significant Developments)

Takeda CFO says plans up to $10 bln in asset sales after Shire -Nikkei
Wednesday, 28 Nov 2018 11:01pm EST 

Nov 29 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA PHARMACEUTICAL CFO SAYS PLANS UP TO $10 BILLION IN ASSET SALES AFTER SHIRE ACQUISITION TO REDUCE INTEREST-BEARING DEBT - NIKKEI.  Full Article

Takeda Pharmaceutical to issue unsecured U.S. dollar denominated senior notes worth $5.5 bln
Monday, 19 Nov 2018 08:47pm EST 

Nov 20 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says it will issue unsecured U.S. dollar denominated senior notes worth $5.5 billion .The Notes will be issued in order to finance a portion of the funds necessary for the acquisition of Shire plc and reduce commitments under the 364-Day Bridge Credit Agreement entered into in connection with the Acquisition on May 8, 2018 .  Full Article

Takeda Pharmaceutical announces issuance of unsecured U.S. dollar denominated senior notes
Thursday, 15 Nov 2018 08:24pm EST 

Nov 16(Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says it announces that it has today, Nov. 15 (London time), launched the offering of its unsecured U.S. dollar denominated senior notes .The Notes will be issued to investors to finance a portion of the funds necessary for the acquisition of Shire plc ((the acquisition)and reduce commitments under the 364-Day Bridge Credit Agreement entered into in connection with the acquisition on May 8 (as amended on June 8 and Oct. 26).  Full Article

Takeda Reaffirms Strategic & Financial Rationale For Shire Acquisition
Monday, 12 Nov 2018 02:02am EST 

Nov 12 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::ANNOUNCES PUBLICATION OF CIRCULAR AND NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS IN RELATION TO PROPOSED ACQUISITION OF SHIRE.REAFFIRMS STRATEGIC AND FINANCIAL RATIONALE FOR SHIRE ACQUISITION.  Full Article

Takeda Says To Hold Extraordinary Shareholders Meeting Dec 5 To Vote On Matters Related To Shire Acquisition
Monday, 12 Nov 2018 02:00am EST 

Nov 12 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA SAYS TO HOLD EXTRAORDINARY SHAREHOLDERS MEETING DEC 5 TO VOTE ON MATTERS RELATED TO SHIRE ACQUISITION.  Full Article

Takeda Announces Issuance Of Unsecured Euro Denominated Senior Notes
Thursday, 8 Nov 2018 03:00am EST 

Nov 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA ANNOUNCES ISSUANCE OF UNSECURED EURO DENOMINATED SENIOR NOTES.  Full Article

Shire Q3 Revenue Rises 5 Pct To $3.87 Bln, Takeda Deal On Track To Close In H1 2019
Thursday, 1 Nov 2018 08:00am EDT 

Nov 1 (Reuters) - Shire PLC ::SHIRE PLC - PRODUCT SALES GROWTH OF 6% AND CONTINUES TO EXECUTE AGAINST KEY PRIORITIES IN Q3 2018.SHIRE PLC - TAKEDA'S PROPOSED ACQUISITION OF SHIRE REMAINS ON TRACK TO CLOSE IN H1 2019.SHIRE PLC - Q3 TOTAL REVENUES OF $3,872 MILLION REPRESENTING GROWTH OF 5%.SHIRE PLC - Q3 OPERATING INCOME INCREASED 35% TO $956 MILLION.SHIRE PLC - QTRLY DILUTED EARNINGS PER ADS $1.75.SHIRE PLC - QTRLY NON GAAP DILUTED EARNINGS PER ADS $3.64.SHIRE PLC - Q3 NON GAAP EBITDA MARGIN WAS SLIGHTLY DOWN TO 42% (Q3 2017: 44%).SHIRE PLC - CONTINUE TO EXPECT TO ACHIEVE MID-FORTIES NON GAAP EBITDA MARGIN BY 2020.SHIRE PLC - PROJECTED 2020 REVENUE TARGET UPDATED TO $16.5 - $17.5 BILLION, REFLECTING REMOVAL OF $0.5 BILLION OF ONCOLOGY SALES IN ORIGINAL PROJECTION.SHIRE PLC - SEES FY TOTAL REVENUE $15.3 - $15.8 BILLION.SHIRE PLC - SEES FY DILUTED EARNINGS PER ADS $7.17 - $7.77.SHIRE PLC - SEES FY NON GAAP DILUTED EARNINGS PER ADS $14.77 - $15.37.  Full Article

Takeda CEO Says R&D Budget Will Be More Than 400 Bln Yen After Shire Acquisition, Making Takeda More Competitive Globally
Wednesday, 31 Oct 2018 03:43am EDT 

Oct 31 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>: :TAKEDA CEO SAYS RESEARCH AND DEVELOPMENT BUDGET WILL BE MORE THAN 400 BILLION YEN ($3.5 BILLION) AFTER SHIRE ACQUISITION, MAKING TAKEDA MORE COMPETITIVE GLOBALLY .  Full Article

Takeda Proposes Divestment Of Shire Drug Compound To EC For Deal Approval
Monday, 29 Oct 2018 03:00am EDT 

Oct 29 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::STATEMENT REGARDING ONGOING EC PHASE I REVIEW.IN DISCUSSIONS WITH EC RELATING TO OVERLAP IN AREA OF INFLAMMATORY BOWEL DISEASE BETWEEN CO'S ENTYVIO AND SHIRE'S SHP647.COMPANY REMAINS COMMITTED TO ENTYVIO.CONFIRMS THAT THERE ARE NO DISCUSSIONS WITH EC REGARDING ANY OTHER MARKETED PRODUCTS OR ASSETS IN PIPELINE.DOES NOT ANTICIPATE THAT DISCUSSIONS WITH EC WILL RESULT IN A DELAY TO TIMETABLE FOR COMPLETION OF SHIRE TRANSACTION.PROPOSED TO EC A REMEDY OF A POTENTIAL DIVESTMENT OF SHP647 AND CERTAIN ASSOCIATED RIGHTS.  Full Article

Takeda Announces New Financing Agreements Related To Shire Deal
Friday, 26 Oct 2018 02:01am EDT 

Oct 26 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::ANNOUNCES EXECUTION OF SENIOR SHORT TERM LOAN FACILITY AGREEMENT AND SUBORDINATED SYNDICATED LOAN AGREEMENT.ALSO ANNOUNCES EXECUTION OF SECOND AMENDMENT TO BRIDGE CREDIT AGREEMENT IN CONNECTION WITH PROPOSED ACQUISITION OF SHIRE.ENTERED INTO A SENIOR SHORT TERM LOAN FACILITY AGREEMENT FOR UP TO 500 BILLION JAPANESE YEN.SENIOR SHORT TERM LOAN FACILITY WILL FINANCE A PORTION OF FUNDS NECESSARY FOR ACQUISITION OF SHIRE.ALSO ENTERED INTO A SUBORDINATED SYNDICATED LOAN AGREEMENT FOR UP TO 500 BILLION JAPANESE YEN.AGREEMENTS SUPPORT INTENTION TO MAINTAIN DIVIDEND POLICY & INVESTMENT GRADE CREDIT RATING FOLLOWING SHIRE DEAL CLOSE.  Full Article

Photo

Takeda clears key hurdle as investors back $59 billion Shire deal

OSAKA Takeda Pharmaceutical has won shareholder approval for its $59 billion takeover of London-listed Shire , creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt. | Video